GlassScriptPhysician profile
Jesse Stawicki
NPI 1497732598
$22,752.77
in general payments reported to CMS, 2019-2025
37 companies · $2,374 in 2025
The $2,374 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,627 · 2020: $3,379 · 2021: $2,943 · 2022: $3,915 · 2023: $3,158 · 2024: $3,355 · 2025: $2,374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,877 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,876.62 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,499.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Kowa Pharmaceuticals America, INC. | $1,617.17 | 2019-2025 | Seglentis, Livalo, Zoryve |
| Novo Nordisk INC | $1,611.17 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,559.63 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $1,505.24 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,494.15 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $1,269.93 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $1,055.97 | 2020-2025 | Viberzi, Linzess |
| Amarin Pharma, INC. | $1,032.67 | 2019-2023 | |
| Pfizer INC. | $1,008.57 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $870.82 | 2019-2025 | Xifaxan |
| Allergan, INC. | $818.28 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $595.19 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $550.67 | 2019-2024 | Xarelto |
| Abbott Laboratories | $265.35 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Stawicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.